TIDMPRTC
PureTech Health PLC
20 October 2020
20 October 2020
PureTech Health plc
PureTech Founded Entity Vor Biopharma Appoints Matthew R
Patterson to its Board of Directors
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Vor Biopharma, today announced the appointment of Matthew R
Patterson, a biotechnology executive with nearly 30 years of
experience in research, development, and commercialisation of
innovative treatments, to its Board of Directors.
Mr Patterson has held senior leadership positions in both
private and publicly-traded biotechnology companies. He is the
co-founder of Audentes Therapeutics and was its Chief Executive
Officer for eight years until its acquisition by Astellas Pharma in
2020; he also chaired the company's Board of Directors and
continues to serve as a strategic advisor to the company. Prior to
Audentes, Mr Patterson was an entrepreneur-in-residence with
OrbiMed. Earlier in his career, he worked for Genzyme Corporation,
BioMarin Pharmaceutical and Amicus Therapeutics.
The full text of the announcement from Vor is as follows:
Vor Biopharma Appoints Matthew R Patterson to its Board of
Directors
CAMBRIDGE, Mass. - October 20, 2020 - Vor Biopharma , an
oncology company pioneering engineered haematopoietic stem cells
(eHSCs) for the treatment of cancer, today announced the
appointment of Matthew R Patterson, a biotechnology executive with
nearly 30 years of experience in research, development, and
commercialisation of innovative treatments, to its Board of
Directors.
"Matt is a highly respected leader in biotech, and for good
reason," said Robert Ang, MBBS, MBA, Vor's President and Chief
Executive Officer. "His expertise, guidance, and insights will be
critical as we continue to advance our science towards the goal of
developing potentially transformative therapies for patients with
blood cancers."
Mr Patterson has held senior leadership positions in both
private and publicly-traded biotechnology companies. He is the
co-founder of Audentes Therapeutics and was its Chief Executive
Officer for eight years until its acquisition by Astellas Pharma in
2020; he also chaired the company's Board of Directors and
continues to serve as a strategic advisor to the company.
Additionally, he is a member of the Board of Directors of Homology
Medicines, Inc., and the Board of Directors of 5:01 Acquisition
Corp. Mr Patterson also currently serves as the Chairman of the
Alliance for Regenerative Medicine (ARM), the international
advocacy organisation representing the gene and cell therapy and
broader regenerative medicine sector.
Prior to Audentes, Mr Patterson was an entrepreneur-in-residence
with OrbiMed. Earlier in his career, he worked for Genzyme
Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Mr
Patterson received his bachelor's degree in biochemistry from
Bowdoin College.
"Vor's innovative approach to cell therapy and passionate team
have the potential to transform the lives of cancer patients," Mr
Patterson said. "I am excited to provide guidance and mentorship to
Robert and the team as they continue to build a world class cell
therapy company."
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered haematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumour cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both haematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies,
and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
haematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, we believe that
CD33 will become a far more cancer-specific target, potentially
avoiding toxicity to the normal blood and bone marrow associated
with CD33-targeted therapies. Vor aims to improve the therapeutic
window and effectiveness of CD33-targeted therapies, thereby
potentially broadening the clinical benefit to patients suffering
from acute myeloid leukaemia.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have received US Food and Drug Administration (FDA) clearance
and European marketing authorisation. All of the underlying
programmes and platforms that resulted in this pipeline of product
candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the addition of Mr Patterson to
Vor's Board of Directors and the potential to become a world class
cell therapy company and those risks and uncertainties described in
the risk factors included in the regulatory filings for PureTech
Health plc. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPGBCUUPUPGB
(END) Dow Jones Newswires
October 20, 2020 08:08 ET (12:08 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Aug 2023 to Aug 2024